Abstract
Agios has reported the first mutant-selective inhibitors of the metabolic enzymes IDH1 and IDH2 and has shown therapeutic effect in preclinical cancer models. The company has a partnership with Foundation Medicine to develop companion diagnostics to identify patients with cancer who have the mutations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
